



Thomas Wolfram Paul Friedl

Contact

Thomas Wolfram Paul Friedl

Publications (4)

Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. *Clin Chem* 2024; 70:307-318.

De Gregorio A, Friedl T, Hering E, Widschwendter P, De Gregorio N, Bekes I, Janni W, Davut D, Huober J. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors. *Oncology* 2021; 99:780-789.

De Gregorio A, Rothenbacher D, Janni W, Schmitt M, Kuhn P, Wiesmüller L, Friedl T, De Gregorio N, Ebner F, Felberbaum R, Thiel F, Kühn T, Flock F, Fritz S, Schlicht E, Rempfen A, Möller P, Nagel G, Huober J. Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. *Arch Gynecol Obstet* 2019; 301:273-281.

De Gregorio A, Widschwendter P, Ebner F, Friedl T, Huober J, Janni W, De Gregorio N. Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB. *Oncology* 2019; 98:91-97.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch